Incyte (INCY) Current Deferred Revenue (2016)
Historic Current Deferred Revenue for Incyte (INCY) over the last 7 years, with Q3 2016 value amounting to $2.9 million.
- Incyte's Current Deferred Revenue fell 7769.31% to $2.9 million in Q3 2016 from the same period last year, while for Sep 2016 it was $2.9 million, marking a year-over-year decrease of 7769.31%. This contributed to the annual value of $12.5 million for FY2015, which is 285.71% down from last year.
- Incyte's Current Deferred Revenue amounted to $2.9 million in Q3 2016, which was down 7769.31% from $6.1 million recorded in Q2 2016.
- Incyte's 5-year Current Deferred Revenue high stood at $67.0 million for Q1 2012, and its period low was $2.9 million during Q3 2016.
- Over the past 5 years, Incyte's median Current Deferred Revenue value was $12.9 million (recorded in 2014), while the average stood at $27.3 million.
- In the last 5 years, Incyte's Current Deferred Revenue changed by 0.0% in 2012 and then crashed by 8049.3% in 2013.
- Quarter analysis of 5 years shows Incyte's Current Deferred Revenue stood at $66.1 million in 2012, then crashed by 80.49% to $12.9 million in 2013, then fell by 0.08% to $12.9 million in 2014, then decreased by 2.86% to $12.5 million in 2015, then tumbled by 77.08% to $2.9 million in 2016.
- Its Current Deferred Revenue stands at $2.9 million for Q3 2016, versus $6.1 million for Q2 2016 and $9.3 million for Q1 2016.